Korsana Biosciences Exits Stealth with $175M
Longevity biotech firm Korsana Biosciences has emerged from stealth with $175 million in funding. The company aims to develop biologics that target neurodegenerative diseases. Korsana is utilizing advanced delivery platforms designed to improve access to the brain.
- The total $175 million in funding is composed of a $25 million seed investment from 2024 and a $150 million Series A that closed in September 2025. - Key investors in the Series A financing were co-led by Wellington Management and TCGX, with participation from J.P. Morgan Life Sciences Private Capital, Sanofi Ventures, and Foresite Capital. - The company's lead program, KRSA-028, is a monoclonal antibody that targets the amyloid beta protein associated with Alzheimer's disease. - Korsana's proprietary THETA™ platform is a "shuttle" technology designed to transport biologic drugs across the blood-brain barrier, a significant challenge in treating neurological disorders. - The company is led by CEO Jonathan Violin, a venture partner at Fairmount and the former founding CEO of several other biotech companies, including Viridian Therapeutics and Dianthus Therapeutics. - Korsana is a spinout from the venture creator Paragon Therapeutics, which also developed the technology behind KRSA-028. - The company anticipates initiating human clinical studies for KRSA-028 by early 2027, with initial safety data expected by the middle of that year and proof-of-concept results by the end of 2027. - Unlike current intravenous treatments for Alzheimer's, Korsana is developing KRSA-028 to be administered as a low-volume subcutaneous injection, aiming to be more convenient for patients and caregivers.
